Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 May;56(5):725-32.
doi: 10.1136/gut.2006.103564.

Risks and benefits of biologic therapy for inflammatory bowel diseases

Geert D'Haens  1
Affiliations
Review

Risks and benefits of biologic therapy for inflammatory bowel diseases

Geert D'Haens. Gut. 2007 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing of interests: Dr D'Haens has acted as a consultant, investigator and speaker for Centocor, Schering‐Plough, Abbott, UCB, Elan and PDL.

References

    1. Blonski W, Lichtenstein G R. Complications of biological therapy for inflammatory bowel disease. Curr Opinion Gastroenterol 20062230–43. - PubMed
    1. Van Assche G, Van Ranst M, Sciot R.et al Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005353362–368. - PubMed
    1. Suntharalingam G, Perry M R, Ward S.et al Cytokine storm in a phase 1 trial of the anti‐CD28 monoclonal antibody TGN1412. N Engl J Med 20063551018–1028. - PubMed
    1. Sackett D L. Bias in analytical research. J Chronic Dis 19793251–63. - PubMed
    1. Lichtenstein G R, Feagan B G, Cohen R D.et al Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 20064621–630. - PubMed